Latest / Psychopharmacology Today / Ep. 7: Mixed States and the Bipolar Spectrum: Improving Diagnosis and Treatment Decisions
Transcript
- 0:05Our speaker this evening, Dr.
- 0:06Phelps, has focused his psychiatric practice on complex mood disorders for over 20 years.
- 0:13He's served on the International Society for Bipolar Disorders' Diagnosis and Chronotherapy Task Forces.
- 0:20He founded the website psycheducation.org in 2000, and recently a simpler, shorter version:
- 0:28depressioneducation.org, leading to book invitations: "Why Am I Still Depressed?
- 0:34for Patients and Families," "A Spectrum Approach to Mood Disorders for Professionals." Currently, Dr.
- 0:41Phelps is completing YouTube@Ed's @PsychEducation, presenting the same material in 30 five-minute videos.
- 0:50So thank you very much for joining us, Dr.
- 0:52Phelps, and it is yours.
- 0:54Thank you very much, Phil.
- 0:56And thank you to Dr.
- 0:58George Kapalka for introducing me to your group.
- 1:01The message that I have to share here is worth your time, I hope you'll find.
- 1:05And I'm honored to have the opportunity to talk with you all.
- 1:08All right, here we go.
- 1:09So our objectives for this evening, basically talking about diagnosis and treatment of mixed states.
- 1:15We'll go beyond the DSM criteria and then look at the resulting differential that leads to this overlap with PTSD, GAD, ADHD, borderline, that is so profound.
- 1:26It means that I think uncertainty is wisdom.
- 1:29It's the right place to find yourself if it's really not clear.
- 1:32And I think often it should not be.
- 1:34And then I'm going to offer you three different ways to cope with that uncertainty.
- 1:38Then I'd like to actually pause for a little bit of a sort of interlude and talk about who can do the diagnosis and treatment.
- 1:46This is in part what led to this invitation because I'd like to encourage you as a psychiatrist that prescribing psychologists
- 1:55I think are in many respects ideally suited to be doing the diagnosis and treatment in this very complicated and difficult and so prevalent realm.
- 2:04And then we'll get on to treatment, talk about mood stabilizers and destabilizers.
- 2:09And I have a particular interest in antidepressant tapering, which I think is also the potentially domain of prescribing psychologists and perhaps psychologists who are not
- 2:20prescribing as well.
- 2:21Always important not to just gloss over disclosures.
- 2:25I've written a couple of books about bipolar disorders.
- 2:28I do get royalties for those.
- 2:29I'm going to encourage you not to buy them because there are three resources instead, including depressioneducation.org and YouTube @PsychEducation, for which I make zero
- 2:39money.
- 2:39And I will also talk about medications that are off-label.
- 2:43If you just assume that really everything is in this context, you'd be pretty close to correct.
- 2:48So I'm gonna invite you to think through this presentation about one particular patient who, odds are, could easily end up in your one or two sessions that you have per week for
- 3:00new patients:
- 3:01A 32 year old named Kaya who is presenting with depression.
- 3:05Well, as you know, the first thing to do, according to the DSM, is to decide whether that depression is unipolar or bipolar.
- 3:14First thing, at least in the sense of if there's going to be a medication to be considered, this is a very important distinction.
- 3:20Well, I hope that you've come to recognize that, no, really the question is:
- 3:25Where is Kaya on the spectrum of mood?
- 3:28How bipolar is she?
- 3:30This used to be kind of an outlier way of thinking about things, the spectrum approach to diagnosis.
- 3:35But in the last 20 years, it's amazed me that it's taken this long.
- 3:40But the field of psychiatry, at least, not so sure about psychology, I hope likewise, has really come to recognize that sure enough, bipolar disorders exist on a spectrum across
- 3:52this mood all the way from unipolar to bipolar.
- 3:54This is no longer really contentious.
- 3:56It doesn't interfere with the DSM.
- 3:59The DSM does okay for diagnoses at the extremes, polarly bipolar, polarly unipolar, but there is a broad middle where it's really not so clear and a spectrum approach to
- 4:11diagnosis is more accurate and I think is more likely to lead to effective treatments and less potential for doing harm.
- 4:20The reference there, by the way, is from the most recent guidelines for the treatment of mood disorders.
- 4:25Jen Malhi is the lead author.
- 4:26This is from Australia and New Zealand.
- 4:28There's a somewhat earlier one from the Canadian Mood and Anxiety Treatment Program that coupled with the International Society for Bipolar Disorders for their guidelines.
- 4:38And most of what I'm talking about here is in those guidelines.
- 4:41And I'll tell you when I'm saying something that's not.
- 4:45A mixed state then is, you can think of it as this realm of the mood spectrum that's not clearly bipolar because if it did meet criteria for bipolar, we wouldn't call it a mixed
- 4:56puzzle.
- 4:57It might be a, you might call it a Bipolar II mixed state.
- 5:01But the problem is people who don't have a bipolar diagnosis and are in this particular spot on the mood spectrum, how do we recognize that Kaya, for example, is there, not
- 5:12bipolar, but not unipolar.
- 5:14And the reason this is so important is because antidepressants can worsen this part of the mood spectrum.
- 5:21And indeed, they can actually cause it in people who are not currently on an antidepressant.
- 5:25So let's talk about what is a mixed state.
- 5:28Well, it's depression.
- 5:29And don't forget, in everything I'm saying here, there's depression, there's not like a given, but it's what else is there.
- 5:36And so I'm inviting you to consider now:
- 5:38What else is it beyond depression that makes, what makes it mixed?
- 5:44There's the DSM criteria, of course, but those are now 12 years old.
- 5:47And we have data suggesting that we can actually use a database approach to defining this, as I'll show you in a moment.
- 5:55Anxiety, anger, agitation, and attention problems, the so-called "4 A's," are actually among the most common, and in one study, the most common symptoms of a bipolar mixed
- 6:09state.
- 6:09The references here, Roger McIntyre there in red, his paper in particular, with Trish Suppes from Stanford, and then the other one here from Nasir Ghami and Company,
- 6:20his mentor, Anastasio Koukopoulos, using these different criteria and validating that these are more common than the ones that are listed in the DSM.
- 6:31Well, as you are anticipating, and maybe have learned already from experience, if you add these to depression, well, you end up with a bunch of patients that you see all the time,
- 6:43right?
- 6:43I mean, this probably, I would think this is one of the most common presentations that you see,
- 6:48whether it's attention problems with depression, it's ADHD or ADHD comorbid with major depressive disorder and so on across that list.
- 6:58So I'm presuming I'm talking about a bunch of your patients.
- 7:01You might have diagnoses like PTSD plus depression or generalized anxiety.
- 7:05If they're doing great, we wouldn't even need to worry about this.
- 7:08But if they're not doing great, we need to back up a step.
- 7:11Someone once said, I think, when your treatment isn't working, reconsider your diagnosis.
- 7:16So let's back up a step and wonder about the differential diagnosis across this mix.
- 7:22If you take the depression symptoms (check marks here in blue) and combine them with the symptoms that belong to these various conditions, you end up with this overlap map that I
- 7:33think is nearly 100%.
- 7:35Now there are other symptoms that go with those other conditions, but they share these with bipolar mixed states.
- 7:41So, how are you then supposed to cope with this overlap?
- 7:45Trying to differentiate these conditions based on symptoms is a fool's errand.
- 7:50I think it's impossible.
- 7:51But there are other ways to do this, and I'm going to show you three.
- 7:54First is to assess non-manic markers: family history, age of onset, course of illness, how cyclic is it, postpartum onset, ever psychotic, and particularly energized negative
- 8:07responses to antidepressants or even really positive ones.
- 8:11So I hope these are familiar, like not coming from nowhere to you, but I'll take the opportunity because you're psychologists
- 8:18to show you a little bit of the literature behind these, including not only the citations, which you can see are old.
- 8:25This has been around, this perspective on how to identify other statistically associated features of bipolar, meaning when they're present, the probability of bipolarity is higher
- 8:37than when they're absent.
- 8:38They don't make diagnoses.
- 8:39They shift the probabilities.
- 8:43They're so important that a group at mostly Mass General
- 8:45many years ago said, "Let's have a bipolarity index." And they gave those four dimensions a fifth cousin, the smooth symptoms, the symptoms of bipolar, and it gave them each 20
- 8:57points.
- 8:58And the reason I'm pointing you at the bipolarity index is not because I think you should use it.
- 9:02It's really quite cumbersome.
- 9:04Really, as far as I know, no one's using it regularly, although it has been validated, in fact, three times
- 9:09in the sense that it identifies bipolar disorder quite well.
- 9:13But the reason to show it to you is because I want you to see the authors of the Bipolarity Index gave 80% of the weight to the non-manic bipolar markers.
- 9:24So these are not like cute little things to do in addition to really focusing on the symptoms.
- 9:29I think it should be the other way around.
- 9:31You should be focusing on these things and the symptoms are just not going to help you very much
- 9:36because they overlap too much with those other conditions.
- 9:39So I'm always very interested in these things.
- 9:41Now, the problem, of course, is you're very busy gathering a ton of data and trying to establish rapport with your new client so that you can go somewhere with your treatment
- 9:52relationship.
- 9:53So you're very busy in an initial interview.
- 9:56And I'm suggesting that you should be more diligent about getting more information about the bipolar stuff?
- 10:02I think that's
- 10:03a big ask.
- 10:04So there's another way to do this.
- 10:06And so on top of everything else, you might just use, for example, a questionnaire.
- 10:11Here's one.
- 10:12I have no financial interest in this whatsoever, but I did generate it using my colleagues.
- 10:19Ron Pye has developed this thing called the BSDS, the Bipolar Spectrum Diagnostic Scale.
- 10:25It has been several times validated, the BSDS alone,
- 10:28effectively identifying bipolar, bipolar II slightly better than the MDQ, the Mood Disorders Questionnaire, for example.
- 10:35So the BSDS is a questionnaire for bipolar spectrum in particular.
- 10:40Well, let's combine with that the non-manic markers in a questionnaire format.
- 10:44And then you have this thing called MoodCheck.
- 10:47So I've been using this for a long time.
- 10:49My clinic used it as a...
- 10:51required entry questionnaire that everybody who came in for a new eval got this thing.
- 10:56I think it's extremely useful used in that way.
- 10:58But whether that fits with your flow or not, we'll have to see.
- 11:01Where do you go get this thing?
- 11:02Well, you can Google it.
- 11:04One place would be depressioneducation.org, which has an online version as well as instructions to patients to complete it on their own and score it on their own.
- 11:13Again, I don't make any money.
- 11:15There's no vested interest for me in depressioneducation.org, other than trying to distribute the ideas that you're hearing this evening.
- 11:21Now you're probably quite familiar with the Rapid Mood Screener, the kind of new entrant in this world of bipolar screening.
- 11:28And it is efficient in the sense that it's only six questions.
- 11:32Interesting that it was sponsored by this pharmaceutical company.
- 11:36And I think that might be the reason why it has
- 11:3932% false negatives in this follow-up study on bipolar II; it happened to be in China.
- 11:44But when they incorporated people with bipolar II, the false negative rate shot up.
- 11:49And I've corresponded with Roger McIntyre, one of the lead authors.
- 11:53I think one of the reasons why they set it the way they did is because of that pharmaceutical company's involvement.
- 11:59But whether that's true or not, it's clear that this thing is not sensitive enough to function as a screening tool if this is all you do,
- 12:07even though it does include some of the non-manic markers, not family history, unfortunately.
- 12:13So my colleague Sara Schley and I have an article we've submitted to the Journal of Bipolar Disorders.
- 12:20It's in review now.
- 12:21I hope they're going to send us the reviewers' comments shortly.
- 12:25And we said, to increase the sensitivity, just go back to the data that's in the literature, three episodes
- 12:32not six identifies people who have a higher probability of their depression being a bipolar depression.
- 12:39Three episodes, not six.
- 12:41Likewise, except depression's age of onset as the first episode of depression, up to age 25 as being statistically associated with bipolar.
- 12:54It's true that 18 to 21 is probably the most suggestive,
- 13:00but to cut it off at less than 18, as does the RMS, is really not consistent with the literature.
- 13:06And then finally, don't use a cutoff, don't score it as a yes or no, simply use it as a data-gathering tool.
- 13:13And if your client endorses two or more features from this scale, then you really need to investigate further.
- 13:19For example, you could then give them MoodCheck.
- 13:22If you're not trying to burden them with MoodCheck for everybody who walks in the door, you could do this one for everybody and then follow up with MoodCheck for anyone who has a
- 13:30two or more.
- 13:32I think frankly a one or more, but the data from the RMS suggest two as we've suggested in our paper that we hope will be out soon.
- 13:41So we have this dilemma and that's the first of three means of coping
- 13:47is to assess the non-manic markers as additional means of differentiating, establishing the probability of bipolar relative to these other potential explanations.
- 13:58I'm gonna take a quick look at the chat if I can.
- 14:00BSDS valid with adolescents?
- 14:02Good question.
- 14:03Only studied in adults.
- 14:05Adolescence gets really complicated as you may know.
- 14:08There's a 2024 paper.
- 14:10The main, the principal author is Eric Jungstrom.
- 14:14So if you look at screening for bipolar in pediatric population, there's a beautiful review by Eric Jungstrom and colleagues that talks about different instruments.
- 14:24What you'll see is that nothing is very good.
- 14:26The MDQ kind of comes out on top.
- 14:28So,
- 14:29that's what we can say about screening in pediatrics.
- 14:31Akiskal criteria?
- 14:33Well, people joke about it.
- 14:35Dr.
- 14:36Hagop Akiskal having chopped bipolar up until like bipolar three and a half and four and a half.
- 14:41But Dr.
- 14:41Akiskal was one of the main drivers of recognizing this spectrum nature of bipolar.
- 14:46So I completely agree with him.
- 14:49And I think now most specialists too, I think nearly everyone.
- 14:52Yeah, anxiety usually comes hand in hand, I agree.
- 14:55So the diagnosis is challenging indeed.
- 14:57So a second means of coping with this diagnostic uncertainty.
- 15:01Well, you can recruit the patient as I'm sure you may have done to some degree kind of routinely explaining, "Well, there's this thing you see, it's called the mood spectrum.
- 15:10And we're trying to figure out where on that you might be, not necessarily are.
- 15:14And then there are these things called mixed states." And it ends up being a lot of hand waving, but that can be a very useful part of generating your relationship with the
- 15:23patient.
- 15:23For example,
- 15:24I'd probably wave my hand up and down and say, "You know, bipolar, it sounds like the North and the South Pole, but really, no, it's actually more like the axes of a graph:
- 15:33manic axis, oppressive axis, and you can have any combination of these two symptoms." So for people with bipolar II in particular who've wandered around this territory, this can
- 15:44be very reassuring that they don't have something really weird.
- 15:47They have a very common experience of bipolarity.
- 15:50So I think what I'm suggesting is that we acknowledge not our ignorance, but staying humble to the several possibilities and share that with our clients/patients.
- 16:00One of the ways that I phrase that is, "You don't have bipolar disorder, but you don't have plain depression either because you have this family history you see and your
- 16:09episodes of depression have been kind of like recurrent, not just one or two, but
- 16:15they just keep coming back.
- 16:16And so we really have to consider this bipolar part of a potential explanation for what you have." Not trying to wave your hands around forever, I tried to write the whole thing
- 16:25down in planning this for patients and families.
- 16:27It led to the books.
- 16:29That was the old one, the psycheducation.org, somebody pointed out to me that the modern acronym TLDR,
- 16:35"too long, don't read." I was like, "No, no, people don't operate like this anymore.
- 16:39They need this short one." So this is the short version of psycheducation.org, about 40 pages and links between all the steps.
- 16:49In my attempt to take people who have no ability to get any information about their depression, start from the beginning, everything you need to know before you select a
- 16:57treatment.
- 16:58You might want to just hop around and see if there's any pages in there that you think might be useful for your clients.
- 17:03This is what it looks like.
- 17:05I'm gonna make one other reference to this.
- 17:06And again, I don't have any financial or other gain from this.
- 17:10You know, nowadays people don't read books, they don't read websites even, they want a YouTube video.
- 17:16So I've now completed this thing.
- 17:18There are 50 short videos; no more than 10 minutes.
- 17:21Shooting for five, they're between five and 10 minutes.
- 17:24I'm trying to do everything that the website does.
- 17:27There's a section there on mixed states, use of antidepressants and all of the psychotropics that we use in bipolar disorder.
- 17:34It would take you a long time to work through this thing, but you might see if there's anything in particular.
- 17:38I'm going to reference antidepressant tapering, for example, as a video on there.
- 17:42However, you might still have a few people who can read a book.
- 17:45And if you did, there is one fantastic book that talks about the
- 17:50experience of bipolar that's not manic.
- 17:52As you may know, at least two out of three, some people would say more, people with bipolar do not have mania.
- 17:59They have Bipolar II or subthreshold bipolarity or a mixed unipolar depression, mixed major depression.
- 18:06And so for those people trying to help understand that bipolarity is not bipolar one mania,
- 18:12as everyone thinks it is.
- 18:14This is the best book I've ever seen on that.
- 18:17So readable.
- 18:18And I have no financial connections to this one either.
- 18:22Although Sara Schley the author and I have collaborated on a number of things since I read this book, including this: Brainstorm The Film.
- 18:30Sara drove the gathering of $1.2 million in private donations and fund this, done by a professional videographer,
- 18:39video maker, science, documentarian, they've done things on PBS, Nova and other things.
- 18:46So, there's two ways, calming down again for a moment.
- 18:50And we have one more and that will take us into our little segue.
- 18:54So the third one is to, with your client, your patient,
- 18:57compare the risks of treatment.
- 19:00And I'm going to introduce that way of thinking and then take a segue and then come back to this when I've convinced you, if you had any doubt, that this is your territory and
- 19:10it's really important territory for you.
- 19:12Think now about the treatments for someone with depression and PTSD or depression with GAD, ADHD, or borderlinity.
- 19:22What treatments would you consider for them?
- 19:24Well, being psychologists, which is one of the reasons why I think you have such strength in this territory, you know, you may do yourselves.
- 19:31You certainly know of the existence of these things, certainly one or several, I'm sure, that are specific for these conditions.
- 19:38So if there's still doubt as to whether or not Taya for example, has one of these with depression or a bipolar mixed state, well,
- 19:48if there's no medications involved, we can simply start with one of these psychotherapies and gather more information as we go, not only in terms of response to treatment, but more
- 19:59of the experience that she's having, which will help us diagnostically.
- 20:03But if you then have to consider a medication; someone has referred a patient to you and has already
- 20:09maybe done some of those therapies and is now looking to you for a medication approach.
- 20:13Well, because of that depression, what do we think in here?
- 20:17Well, obviously we're thinking about if you don't invoke bipolarity, you'd be thinking about an antidepressant.
- 20:23Taya might already have had one or two or three or like five by the time she would get to me.
- 20:28So let's look at antidepressants.
- 20:31In the middle of the mood spectrum, we are extrapolating because
- 20:35this is basically an unsteady territory, mixed states.
- 20:38There's like more randomized trials for brand new pharmaceuticals.
- 20:42But otherwise for psychotherapies, for some of our older things like Lamotrigine, mixed states is not a territory that has been studied with randomized trials.
- 20:51So we're extrapolating our experience with antidepressants.
- 20:54And likewise, we're extrapolating our experience with treatments from the clearly bipolar realm.
- 21:00So social rhythm therapy or SRT.
- 21:03We'll a little more about that in a minute.
- 21:05Lamotrigine, low-dose lithium are things that we could consider for that middle territory that is basically unknown.
- 21:13And so comparing risks is the strategy.
- 21:16Pause for just a moment because I want now to talk to you about sort of something else.
- 21:21We'll come back to that spot right there in a minute.
- 21:23Who is going to deliver these diagnostic refinements and then the treatments that will come as we get a clearer picture of what Taya and anyone else who presents like her might
- 21:36have?
- 21:36Well, this is how I got engaged with Alliant and Dr.
- 21:39Kapalka and you this evening is because I made a video about why we need prescribing psychologists.
- 21:47As a psychiatrist, I'm definitely an outlier in this respect.
- 21:50I thought it's just time for me to speak up.
- 21:53I don't really have to worry about offending my colleagues anymore.
- 21:56I've been an outlier for a long time in that bipolar world.
- 22:00And after 20 years, I'm not an outlier there anymore.
- 22:03I was like with the International Society for Bipolar Disorders when thinking about bipolar spectrum was not the most popular way of thinking.
- 22:10But now it is.
- 22:11So maybe in another 20 years, I don't think I've got quite that long, but we won't be fretting so much about prescribing psychologists.
- 22:19We'll just have more of them.
- 22:21And because we need so many more clinicians to work in this territory that I've been trying to describe, because this is the territory of depression and anxiety and attention
- 22:31problems.
- 22:31This is like the most prevalent stuff, right?
- 22:34Okay, so I'm gonna just show you a few slides from this video.
- 22:38If you really like what I'm saying and you want to show it to somebody else, there's a video version of this on the YouTube channel.
- 22:43So here's the logic.
- 22:44In primary care, after you've sorted out all the other stuff, the stuff that really goes into primary care is attention problems, mood problems, and anxiety problems.
- 22:54And primary care does their darndest to try to help people with those problems.
- 22:59So, they work and work and work.
- 23:00And what comes out of primary care to you is people who are non or under responsive to antidepressants.
- 23:07They've usually had several, maybe an antipsychotic.
- 23:10Particularly in pediatrics, younger people who are non or under responsive to routine stimulants and now many adults as well.
- 23:19So, that's what's coming out of primary care to you.
- 23:22And so, you might invoke these various diagnoses:
- 23:25MDD, PTSD, social phobia, and so forth.
- 23:28But as I have been discussing with you, there is this additional realm, additional set of possibilities to consider.
- 23:37Again, if your patient/client is doing fine, then fine.
- 23:40We don't have to invoke any of the further logic.
- 23:42But if they're not, then we're thinking about medications and psychotherapies.
- 23:46And as I mentioned, the fact that psychologists have the rest of these skills to bring to this, I think is so important.
- 23:54So any of those particular psychotherapies is relevant to this mix.
- 23:58In fact, nearly all of them, I think, could be potentially beneficial.
- 24:03If it turns out to be bipolar, it's still probable that some of these would be beneficial.
- 24:07And all of them are unlikely to make bipolar disorder worse.
- 24:11So a great place to start.
- 24:13But when we turn and think about medications, well...
- 24:16Before we go there, I wanna add one more psychotherapy and that's social rhythm therapy.
- 24:21I think that's less likely to be in your kit bag already.
- 24:25And I'll show you in a minute where you could go to acquire that very simple set of skills.
- 24:31You know how to teach yourself psychotherapies.
- 24:34This is just another one to add to the toolkit.
- 24:37As far as medications goes, I like to think of these as like...
- 24:40Now there's SRIs, SSRIs.
- 24:43Now we ought to coin MSAEs: mood stabilizers with antidepressant effects.
- 24:49It's a separate subset of the mood stabilizers, not all of them.
- 24:54These are those that have antidepressant effects, lamotrigine, low-dose lithium, quetiapine, and lurasidone.
- 25:00That's the subset of medications to consider for this group of patients here at the top.
- 25:05And now we have the whole set of tools
- 25:08that would be relevant to this group of patients.
- 25:11Then there's one other technique that I think we need to bring to this, which is careful antidepressant tapering.
- 25:18As you know, many of these patients, when they arrive in your care, they've already had at least one, often several antidepressants and are very likely to be on one.
- 25:28And antidepressants can cause mixed states and make mixed states worse.
- 25:33One of the tools to bring is, I'll mention later in more detail, is to carefully taper the antidepressant.
- 25:39So the point is, who's going to do all this?
- 25:41I think you all are in the perfect position to be able to do all this as well as, and I think better than, many psychiatrists.
- 25:48And then we can say, you know, ADHD is just kind of part of the same story.
- 25:53It's part of the same differential.
- 25:54And it has the same story in terms of there's a group of medications, but there's also behavioral treatment.
- 26:00Who's going to provide that?
- 26:01You can provide that.
- 26:02That's my rationale.
- 26:03And so that's why I made the video.
- 26:05And one of these days, I'm going to cart this off to my local psychiatry colleagues, but I'm privileged to be able to start with you first.
- 26:14In the Willamette Valley of Oregon,
- 26:16we live at the end of the rainbow where we get to live in a pot of gold.
- 26:20I'm calming down again so we can proceed because we're going to jump back to where we were and pick up with this.
- 26:28As one of your colleagues pointed out, IPSRT.
- 26:31Yeah, interpersonal and social rhythm therapy.
- 26:33So here's my perspective on that.
- 26:35IPSRT is where that all started.
- 26:37Ellen Frank from University of Pittsburgh created IPSRT and the disciples that came out of Ellen Frank's program are trained in IPSRT.
- 26:47It's the combination of interpersonal therapy and social rhythm therapy.
- 26:52But they're really actually different therapies.
- 26:56And if we think about people with bipolar spectrum problems,
- 26:59interpersonal therapy can help tons of people with mood anxiety problems.
- 27:03But it's the social rhythm therapy that is really, I think, the active ingredient in terms of going after the chronobiological disturbances of bipolar disorder.
- 27:12So SRT is in my head and actually in the Australians who are studying this as well, they also call it SRT.
- 27:19So I encourage you to think about just learning SRT, social rhythm therapy.
- 27:23If you already know IPSRT, that's great.
- 27:25Do we consider schizoaffective on the spectrum?
- 27:28Well, if you think of like there is the mood spectrum from unipolar to bipolar, well, there's kind of like a separate continuum from bipolar to schizophrenia that is clearly a
- 27:41continuum, true.
- 27:42And schizoaffective
- 27:44is sort of an awkward name that really merely identifies the middle of that continuum.
- 27:49My take on this, I think simplifies everything is, hey, look, when someone gets diagnosed with schizophrenia, but they have some mood symptoms, the question, the long-term question
- 27:58is, could they be managed with a mood stabilizer alone and not need an anti-psychotic?
- 28:03In other words, are they so far towards psychosis, they're just going to have to have that anti-psychotic component?
- 28:09Or,
- 28:09are they close enough to the mood end where, no, no, the psychotic symptoms are coming from the mood disorder like bipolar one and cause psychosis, even if it's plain old
- 28:20bipolar one.
- 28:21So you don't need to have an antipsychotic to treat psychosis.
- 28:25You need to treat the mood disorder that caused the psychosis.
- 28:28You can do that with other things: lithium, divalproex, valproate.
- 28:32So someone who's over here and getting called schizoaffective, yeah, fine.
- 28:36But
- 28:37that just leaves open the question: Could that be treated with a mood stabilizer alone?
- 28:42How do you get there?
- 28:43Well, you get the mood stabilizer on board and then you cross your fingers and make sure that a lot of the support community is there to be prepared for the reemergence of
- 28:52psychotic symptoms as you gradually, really gradually, 100% with the patient's consent in this case, taper the antipsychotic.
- 29:00So that's my take on schizoaffective disorder.
- 29:02Any medication being formulated for people with bipolar that people would more likely to take or continue to take?
- 29:07Yeah, we're going to talk about Lamotrigine, which I think is the leader in that realm, low-dose lithium.
- 29:12And I'll talk more about that, I think, as another candidate.
- 29:14Those are my top two.
- 29:17There's even a new version of lithium that's being cooked up by a pharmaceutical company
- 29:22because, as you're alluding to, people need to want to take these things in order that they are likely to stay on them.
- 29:29Or ideally, they are able to get good symptom control without having to endure too much in the way of side effects.
- 29:36So we're going to talk about those very medications that I was just mentioning in this next section.
- 29:41Because you are prescribers or contemplating being a prescriber,
- 29:44you need to know more of the details for making this comparison.
- 29:47So let's start with antidepressants.
- 29:49Well, there's all the stuff that you know about antidepressants, but then there's this part that doesn't get anywhere near enough airtime, and that is withdrawal.
- 29:58What is the probability of having moderate to severe withdrawal symptoms for any given person who starts on an antidepressant?
- 30:06Well, as you probably know, that's
- 30:08extremely controversial.
- 30:10You can find answers all the way from 1% to about 50%; lot of variables in there.
- 30:16But I just want to point out to you this article that just came out like a week or two ago.
- 30:20This is Mark Horowitz from the UK.
- 30:23He's done, I think, the most sober analysis of this question
- 30:28of anyone and this is his and colleagues' newest effort in this realm.
- 30:33So they did a survey of people, primary care patients who were also in psychotherapy.
- 30:39That's how they found them.
- 30:40And they said, "Okay, if you've been on antidepressant, have you tried to stop?
- 30:44And they surveyed, I think there's about 300 people in this survey.
- 30:47Well, here's the results: 79% of people said they had some withdrawal symptoms when they tried to stop and about half of them
- 30:54said it was moderate or severe.
- 30:57But the problem with this study, acknowledged by the authors, is that they only had an 18% response rate to their survey.
- 31:04And these people were in psychotherapy, so it's kind of like a, this is not your totally representative sample.
- 31:09So you could kind of quibble with this 45% moderate, had moderate or severe.
- 31:16But let's say you do want to quibble.
- 31:16Let's say you go, that leaves
- 31:1882% of the non-respondents, let's say all of the non-respondents had no withdrawal.
- 31:27Okay, now let's do the math.
- 31:29That means we're gonna look at 45% of the 18%.
- 31:33That comes to one in 13.
- 31:35So one in 13 people with moderate or severe depression amongst
- 31:42everyone who starts an antidepressant.
- 31:45I think this is far too underspoken when people are being offered an antidepressant.
- 31:51I think it's a huge problem for antidepressants.
- 31:54And we need to factor it in when we're looking at comparing the risks of these treatments.
- 31:58Obviously, I'm far more in agreement with Dr.
- 32:01Horowitz than with people who say this is only one or 2%, which not many people say that anymore.
- 32:07But, you know, it's kind of inching up toward 10%.
- 32:10And then we'd all have some rough agreement that, yeah, you know, like maybe one in 10, because I think one in 13 is a very conservative assessment.
- 32:19Yeah, about one in 10 are going to have moderate or severe withdrawal when they try to stop.
- 32:23Here's one more feature of this study that I think is so important: They said, wait a minute, wait a minute, let's separate out the people who were on an antidepressant for
- 32:31more than two years
- 32:32versus those who were on it for six months or less.
- 32:36And let's look at their incidence of withdrawal, severity, and so forth.
- 32:40And here are the results:
- 32:41Any withdrawal, 10 times more common in the people who had been on for that longer period of time.
- 32:47Severity, five more times, five times more likely to be severe.
- 32:5118 times more likely to have a protracted withdrawal.
- 32:54And 27 times more likely to not be able to stop at all.
- 32:59I think it was about a quarter of their respondents were not able to stop at all.
- 33:03Okay, so obviously I'm trying to
- 33:06make antidepressants look bad.
- 33:08In your hands, they probably already look bad and now you have more reason to think so.
- 33:15And then as I alluded to previously, antidepressants can worsen mixed states.
- 33:20The reference for that would be the Australian and New Zealand guidelines.
- 33:24This is one of the figures from their paper where antidepressants induce this.
- 33:28This is their graphic for a mixed state.
- 33:31So anti-depressants: severe withdrawal, worsen mixed states.
- 33:34That's on top of all the usual stuff, sexual dysfunction and weight gain.
- 33:38So how about social rhythm therapy, SRT?
- 33:41Well, what is this thing anyway?
- 33:43The Social Rhythm Therapy Workbook from Holly Swartz, who is one of those disciples of Ellen Frank.
- 33:48And I think it's an under-representation of her to even think of her as a disciple anymore.
- 33:52She is kind of the...
- 33:54I think the leading figure now for us in terms of understanding SRT, social rhythm therapy.
- 33:59She's written a workbook on how to do it.
- 34:01This is written for patients, but as you know, one of the ways to learn therapy is to go get the patient's version and just work through it with someone.
- 34:09That very first time it's new to you and it's new to them.
- 34:12But once you've gone through it, it all looks like familiar territory.
- 34:16Nothing really magic in here.
- 34:18And you're there to help the patient actually do the exercises because as you know, in a workbook method, it's doing the work that gets you the results, not just reading the book.
- 34:29So you are there to see that the work is being done and helping them stick to it, through the book.
- 34:36So wonderful resource, not only for your clients, but for you.
- 34:40Now there's a simpler version because I want to just focus on sleep.
- 34:43I'm a member of the Chronotherapy Task Force for the International Society for Bipolar Disorders.
- 34:49So I have particular interest in this territory, but I think it's now becoming really clear that a uh very large percentage, not everybody, with bipolarity, they have a
- 34:58chronobiologic disturbance that is amenable to control through
- 35:04regular sleep hours, a regular bedtime and a regular rise time.
- 35:09In my view, most of social rhythm therapy is teaching those two things: a regular bedtime and a regular rise time, and all of the stuff that needs to go on around that.
- 35:20Dark therapy, dark bedroom, amber nightlights, dawn simulator, make your bed as soon as you wake up.,
- 35:28get out of bed, morning routine, physical activity, connecting with people, all part of these routines, it's all about sleep control.
- 35:36That's, in my view, that was social rhythm therapy in a nutshell.
- 35:41And I don't think all these sorts would freak out too much of my characterization of that.
- 35:45I made a video about nearly all this stuff.
- 35:46And this is one of them, "Sleep Control for Mood Stability." It's kind of lengthy because this was before I learned about TLDR:
- 35:53too long, don't read.
- 35:54This is really, really step by step.
- 35:57So to save you some work or to work with you in emphasizing a regular bedtime and a regular rise time, one of ways to get there, of course, there is the same schtick is on
- 36:07the website, depressioneducation.org, and here's the video version.
- 36:10So what's the downside of teaching social rhythm therapy?
- 36:13Well, you could be wasting time.
- 36:15It might not help that much.
- 36:16And that's a fair downside.
- 36:18But as you know, those two resources that I just mentioned, cost is not a big issue here, especially if your involvement is mostly just facilitating and they're really doing the
- 36:28work on their own.
- 36:29So how about Lamotrigine?
- 36:30Well, there's the allergy, right?
- 36:32The rash.
- 36:33You know, it gets talked about as like one in a thousand, but it's really only half
- 36:37that common according to this review of 122 randomized trials.
- 36:42So we really ought to be thinking one in 2000.
- 36:44So one in 2000, how rare is that?
- 36:47Well, as you can gather, I'm a Lamotrigine fan.
- 36:50I prescribed it a ton.
- 36:51I started it de novo in hundreds of patients, but not a thousand and certainly not in 2000.
- 36:59So that would mean that somebody like me who uses it over and over over over over again would see
- 37:04a really bad Stevens-Johnson Syndrome rash?
- 37:08Once in my practicing lifetime, maybe.
- 37:11Actually, it would take four of us, because I think I did this about 500 times, it would take four people doing that over and over over over again to get one Stevens-Johnson
- 37:20Syndrome, the dangerous one.
- 37:23So I think that's almost like a non-issue.
- 37:26Well, why do we talk about it so much?
- 37:28Well, there isn't that much else to talk about with Lamotrigine.
- 37:30Aside from this, there are no major risks with lamotrigine, certainly not once you get past the titration phase.
- 37:40Okay, there's some new data about some cardiac conduction stuff, but I think that needs to get sorted out from prior existing conditions that people with bipolarity are more likely
- 37:50to have.
- 37:50So up until recently, there wasn't anything about cardiac.
- 37:53And I think that's mostly a production of like, if you look hard enough, you can find something.
- 37:58In any case, up until very recently, you wouldn't have had to say anything about cardiac conduction.
- 38:02And I think it's way overdoing it to think that someone who's going to start Lamotrigine needs an assessment of their cardiac risk, let alone an electrocardiogram, which often
- 38:13gets invoked for lithium and I have the same analysis there.
- 38:16Nevertheless, Lamotrigine, what else can we say about Lamotrigine?
- 38:20The rash risk goes to nearly zero when the titration phase is complete.
- 38:26So this is actually a temporary risk of 1 in 2000 severe rash.
- 38:32Okay.
- 38:32So obviously I think Lamotrigine has extremely low risk in this particular context.
- 38:38Now, low-dose lithium.
- 38:39Well, I define low-dose lithium as follows: I start people with 150 milligrams, because it's the smallest prescription available in the US.
- 38:48150 nightly, and they're instructed to increase it on their own every four to seven nights until something good happens or something bad happens.
- 38:56Run the dose back down and leave it at that next step lower dose, which presumably didn't have a problem because you wouldn't have gone on to the next one if you'd had one.
- 39:06This is a problem-free diagnose.
- 39:08You get dose, you get to the next dose, you have a problem, you just go back down and keep going until you and I assess how you're doing.
- 39:15Or you've ramped it up to 600 milligrams, at which point we should pause and get a blood level and within a month or two check your TSH again.
- 39:25Because of course you check the TSH, add creatinine, add calcium, a chem panel
- 39:30in addition to the TSH before you started.
- 39:32What are the data supporting this?
- 39:34Well, there's a precedent for doing this in that it's been an adjunct to antidepressants, including in unipolar depression for decades.
- 39:42So, low-dose lithium has been around and used in this fashion that I've just described for a long, long time.
- 39:49What's the literature on low-dose lithium in terms of the treatment of depression?
- 39:53Particularly like mixed states?
- 39:54Forget it, we don't have any data on that.
- 39:56Low-dose lithium in the treatment of bipolar depression, there's like one major study and it was not good.
- 40:02I think they used too much lithium.
- 40:04Frankly, I can't explain why in their hands it didn't work better than a placebo.
- 40:08In my hands, it's been awesome.
- 40:11Not like it works for everybody, but it works a lot.
- 40:13And in fact, the lead author of that one negative study still talks about using low-dose lithium in just the fashion that I'm describing in part because
- 40:22it has what appears almost certainly to be an inherent anti-suicide effect.
- 40:27I've had several patients where their depression didn't get that much better, but they went, "This is really weird.
- 40:32I used to think about suicide all the time and now I don't." So whatever that is, I think that really does belong to lithium.
- 40:40I think there's plenty of precedent for this; enough to justify a prescribing psychologist
- 40:45using lithium in this fashion also.
- 40:47But even low doses of lithium can mess with thyroid.
- 40:51This is a study that we did in our hospital system where we looked at people who had low-dose lithium as defined by low blood level, 0.4 or less.
- 41:00And we looked to see what's the incidence of hypothyroidism in that group compared to the bipolar maintenance group, 0.5 to 0.8, or the
- 41:11bipolar mania treatment group, 0.9 and up.
- 41:14And those are the people who have the highest.
- 41:16So it was dose-related.
- 41:17Highest incidence of hypothyroidism in the 0.8 and up group, moderate frequency in the .5 to .8 group.
- 41:28And down in this low-dose lithium group, it was still there.
- 41:32It was about half the rate, one in 10 for that middle group.
- 41:36These numbers are very flimsy, but they're the only numbers that we have for answering this question about the incidence of hypothyroidism on low doses.
- 41:46But the bottom line is obvious: You just need to keep an eye on TSH in anybody who's going on lithium, including, in my view, on lithium orotate.
- 41:54Now we can pause and breathe and look at where was this all going?
- 41:57It was going here.
- 41:58Remember, this is, Kaya comes in, how bipolar is she?
- 42:02We're not sure.
- 42:03We're living in an uncertain realm.
- 42:05We want to cope with that uncertainty.
- 42:07You and Kaya together, we have non-manic markers.
- 42:11We have educated Kaya about these things, mood spectrum, mixed states.
- 42:17And then we have this third way.
- 42:18"Well, Kaya, you know, after all that, we're still not really sure where you are and how bipolar you might be if at all.
- 42:27But you've tried this and that, you've tried this and that." So now when we come to looking at these options, we can compare their risks.
- 42:35And those are the risks that I think Kaya needs to know as you and she together do shared decision making about deciding what to do.
- 42:43A question: Have I seen unusual fatigue with Lamotrigine?
- 42:47Definitely, especially beyond 200.
- 42:50Below 200, almost never.
- 42:53You know, if you treat enough people, you'll see really anything in somebody.
- 42:57But that's not a common thing except beyond 200, where, yeah, I think the most common thing beyond 200 is people are not cognitively sharp.
- 43:07They start to have difficulty
- 43:09finding words, remembering people's names.
- 43:11They're just a little slower.
- 43:13And interestingly, they often don't come back and complain about it, partly because they may be getting a really good response.
- 43:18Sometimes I have to point it out to them, as I did recently to one of my video colleagues who's been on it for a long time and had to turn the dose up.
- 43:27And he just was not like he usually is.
- 43:30But he hadn't like...
- 43:31snapped like this was Lamotrigine that was doing that.
- 43:34My routine is to ramp up to 150 and watch closely and then go to 200 if necessary and then just keep going all the way up to 400.
- 43:44But the minute I go past 200, I'm warning people about cognitive impairment and watching closely.
- 43:49And yes, I have seen fatigue in that context.
- 43:52When we're thinking about like, you know, antidepressant withdrawal, the definition determines the results, because it depends on how you define withdrawal relative to oops,
- 44:03your symptoms are coming back.
- 44:05So if you just wait for people to like worsen, and then interpret worsening as like, yeah, you're starting to have like mood lability and anxiety and
- 44:13depression symptoms, oh, you're having your old symptoms come back.
- 44:17Oops, no, that can be withdrawal and differentiating between those two as I think you're alluding here, Dr.
- 44:23Fogel, very important, I mean, crucial to understand, is this withdrawal or is this relapse?
- 44:29And yet it's so hard to tell them apart.
- 44:31Actually, Mark Horowitz has a lovely article about this, about ways to differentiate those two things.
- 44:35So you're right.
- 44:36And Ken points out, yeah, if I'm not mistaken, a good percentage experience withdrawal from placebo.
- 44:42Oh yeah, for sure.
- 44:43You tell people what's going to happen and just to warn them that something could happen.
- 44:48And of course, as you know, some people are going to experience that.
- 44:52When you taper off the antidepressant, you want to have a period of baseline with not prescribed medications
- 44:59or start the mood stabilizer as you taper up.
- 45:01Okay, so the question then is, suppose Kaya comes to you and she's on an antidepressant and you think, I think this is a mixed state.
- 45:09I think that antidepressant could be causing it because Kaya even gave you enough history to go, you know, it was kind of wobbly and then I took this antidepressant and then all of
- 45:18this happened.
- 45:19So you're pretty sure this is a mixed state and rather than starting the mood stabilizer,
- 45:24another way to cope with this is just taper that antidepressant.
- 45:28As you know, and probably from experience, Kaya comes in and she's going, you got to help me.
- 45:34Just talking about, well, why don't we just taper that?
- 45:37I got bad symptoms now.
- 45:38You need to do something.
- 45:40So sometimes you feel forced to add something, even when what you really want to do
- 45:46is just taper the antidepressant.
- 45:48And in that context, my favorite thing is, brace yourself, fish oil.
- 45:53It's perfect.
- 45:54It has multiple randomized trials showing efficacy in depression.
- 45:58So it's got an antidepressant effect.
- 46:00It has almost zero risk.
- 46:03It's cheap.
- 46:04It's relatively available.
- 46:06It's like people who don't want to take prescription, don't want to add yet another medication, great, fits for them.
- 46:12And its probability of really helping may not be that big, but it is going to buy time because I've done something while I'm tapering the antidepressant.
- 46:22So that would be one way to try to avoid, as you're alluding to, Dr.
- 46:27Lincoln, adding something at the very same time you're trying to taper an antidepressant where you could get some withdrawal effects.
- 46:33And was that from the antidepressant taper or was that from the thing that we just added?
- 46:38Trying to avoid that conundrum.
- 46:40But sometimes you just have to do it anyway and then just try to cope as you probably have done.
- 46:45Next question: What are my thoughts about pharmacogenomic testing to help with personalized prescribing of medications a) to improve compliance and b) decrease the risk
- 46:54of side effects?
- 46:55A, to improve compliance, if you use it in that way, you're using it not really for the reason for which it was designed, but you might be doing something rather artful and if
- 47:06it's working for you, cool.
- 47:08Because the downside is not that big, even though, you know, we're saddling our medical care system with another, what is it, 350, 500 bucks?
- 47:16Oh, the patient doesn't have to pay for that, but somebody's gotta pay for it, like our medical care system.
- 47:21Could be an artful use of the test.
- 47:24How about decrease the risk of intolerable side effects?
- 47:27Well, one way to cope with that, if you don't know whether the patient is a
- 47:31rapid metabolizer or a slow metabolizer, and you're not in a big hurry, is to start with low doses and work your way up.
- 47:39And then you don't need to know because you're working your way up to response or some problem or some usual ceiling.
- 47:45So as you can gather, I never used it.
- 47:48I'm an old guy, you know, back when I used to walk through this note in school.
- 47:52So this is coming and it will be the way
- 47:56medicine is done in the realm of mental health.
- 47:59I don't think we're there yet.
- 48:00When I looked at some of the reviews, they don't think we're there yet in terms of how much does this really add.
- 48:06But if in your hands, it's really helping you help people?
- 48:10Amen to that.
- 48:11Next question: How do I feel about some people self-medicating with marijuana?
- 48:15So I'm gonna answer this question with a bit of an anecdote.
- 48:18I used to work in a free clinic here in Corvallis, Oregon.
- 48:21I had people come in and say, I want to get this get off this marijuana because I need to have a clean urine test so I can get a job.
- 48:27Good, we're going to swap your medication for one of my medications.
- 48:32And let's see if I can outperform your marijuana.
- 48:36And there were a few people, not really that few, where I never found anything that worked better than theirs.
- 48:42Using marijuana to get to sleep, using marijuana as a mood stabilizer, using marijuana as an anxiolytic.
- 48:49There are people, as you've probably seen, who do get those responses.
- 48:53The other end of the seesaw is, oh my God, it is causing an increased incidence of psychosis in young people, and young people should not be using this if they have any
- 49:04reason to think that they might be at risk of developing a major mental illness.
- 49:08Right...
- 49:09How are you going to convince them about that?
- 49:11It is a very, very sharp sword in both directions.
- 49:15And we should handle it accordingly, meaning that we should not diss it and tell people they shouldn't be using it.
- 49:22And yet at the same time, we need to help society cope with the fact that we're introducing a major risk of
- 49:29mental illnesses, including maybe even inducing some of them that wouldn't happen in the first place.
- 49:34And how are we possibly going to address that in terms of how we make this stuff available?
- 49:41So very, very double-edged.
- 49:43Next question: Lamotrigine in pregnancy.
- 49:46Well, every time I encounter this, I feel like I should go look again, not now, to make sure I haven't missed something new.
- 49:53But the last time I looked,
- 49:54not too long ago, lamotrigine during pregnancy, no data suggesting increased risk of fetal abnormalities.
- 50:01Unlike Divalproate, Valproate, Depakote, or carbamazepine, which definitely carry risks.
- 50:08And as you probably heard, probably best not used in women of reproductive age, like at all, Valproate and carbamazepine, unless you're absolutely back to the wall, as opposed to
- 50:18lamotrigine.
- 50:19No data suggesting increased risk of fetal abnormalities.
- 50:23As you may be alluding to, lamotrigine and estrogen have an interaction with one another.
- 50:28Increasing estrogen cuts lamotrigine roughly in half near the end of pregnancy.
- 50:35So if someone was doing fine on lamotrigine all the way until third trimester and then the depression starts coming back, that's probably because the lamotrigine went down.
- 50:44Should you get blood levels and should you try to be proactive and increase the Lamotrigine in advance of that?
- 50:50That's kind of up to you and the patient.
- 50:51I've never done that.
- 50:52But I didn't probably see enough pregnant women in that phase to become sensitized to it and I think that maybe I ought to be doing that routinely, because maybe that's a good
- 51:01idea.
- 51:02And then you can use blood levels afterward to very carefully and quickly taper the Lamotrigine dose back down to where it was,
- 51:09because as those estrogen level falls, the lamotrigine is going back up.
- 51:13So drug interaction, so to speak, but one very well recognized.
- 51:19Risk to kids, like what about the infant who was born having been exposed to lamotrigine?
- 51:23They seem to do okay and they don't need lamotrigine themselves or a taper after birth.
- 51:29That's a simple answer and I'd have to go back and want to quote the data
- 51:34to be a little more certain about that part of it.
- 51:37I'm pretty sure that's right.
- 51:38Dr.
- 51:39Hall, curious about the dose of fish oil.
- 51:42So fish oil is two things: It is a placebo and it is an active treatment for depression.
- 51:48One version of fish oil is probably a placebo.
- 51:51One version of fish oil has good data, I think, to show that it has an antipresence effect.
- 51:57Which one is that?
- 51:57It's, as you probably learned,
- 51:59750 milligrams to a thousand milligrams of EPA.
- 52:04EPA, not DHA.
- 52:06It can be pure EPA, has to be at least 750 milligrams to a thousand of EPA in a formula
- 52:13that is at least two thirds EPA relative to DHA.
- 52:18So how's your patient supposed to figure that out while they're standing in the grocery store aisle?
- 52:23Well, there's two ways to do this.
- 52:24The best way is you've gone to the local grocery store that's nearest your office and you've purchased the one that you think they oughta get
- 52:32and you hold it up in your office and say, go get that one.
- 52:35Short of that, you say, just make sure that whatever you get, like over the internet, has twice as much EPA as DHA, and has at least 750 milligrams of EPA.
- 52:46And then you're in that realm of the version of fish oil that did in the randomized trials outperform placebo.
- 52:52But if all you want to do is buy time, then you don't have to go through all that.
- 52:58You can just say fish oil because really all you really want right at that moment is the probability of all this actually happening is as you know, you send somebody out to go get
- 53:08that, what are the odds that they're gonna get it, take it, stay on it.
- 53:11Whereas if you just say fish oil, I think the odds are higher and you get the thing that you're looking for, which is buy time.
- 53:19I think that catches us up.
- 53:20So we're going to proceed
- 53:21to how do you treat mixed states?
- 53:23Well, let's start with the official stuff.
- 53:25The treatment guidelines for mixed states.
- 53:29And I'm focusing on mixed depressions because mixed mania, that's simple.
- 53:34You just need to use the antimanics.
- 53:36But do you need, like, where do you switch from this versus that in a depression?
- 53:43Well, according to the treatment guidelines,
- 53:45the two ones, the most recent ones that I cited, oh, look, it's lurasidone because olanzapine, way too much weight gain relative to other options.
- 53:55And cariprazine, it's not generic yet.
- 53:57It's too expensive.
- 53:59It's coming.
- 54:00We'll reassess this later when we have more data, especially some data that wasn't generated by pharmaceutical company sponsored studies.
- 54:07Moreover, treatment guidelines like this are extremely biased toward pharmaceutical
- 54:12company products because to make first line and second line, you need big randomized trials.
- 54:17To have big randomized trials, you need a pharmaceutical company that's seeking FDA approval.
- 54:22That means things like lamotrigine and low-dose lithium don't...
- 54:27in some guidelines like the CanMat, they actually do show up, but they are not likely to be like first line.
- 54:33So you get this instead.
- 54:35So instead, I'm going to share my perspective for this on that, which is...
- 54:40It's kind of simple.
- 54:41You want to decrease the destabilizers and add the stabilizers.
- 54:45I think that's really how you approach the entire mood spectrum beyond plain unipolar depression, because instability is the target.
- 54:55The target is not the mood du jour.
- 54:57If you just wait a couple of months, there'll be a different mood, which means whatever treatment you're doing now may not be appropriate.
- 55:04What you really want to do is stop the cycling.
- 55:07So we need stabilizers, anti-cycling strategies.
- 55:10That is the core ingredient in all treatment of bipolar disorder.
- 55:14Maybe we don't need to add anything.
- 55:16Maybe we can just decrease the destabilizers or maybe we'll look at adding stabilizers.
- 55:21Okay, let's look at the list of those things.
- 55:23So stabilizers and destabilizers.
- 55:26Well, I talked about antidepressants as destabilizers.
- 55:29I'm going to talk more about antidepressant discontinuation, some atypicals.
- 55:35The rest of that probably familiar to you, not surprising.
- 55:38I'm just talking about the really big one there.
- 55:41Stabilizers, social rhythm therapy, definitely a stabilizer for the majority of people with bipolar, not everybody.
- 55:47Lithium, lamotrigine, omega-3s, I think there's a sliver of data suggesting that they have a mood stabilizer effect.
- 55:55Atypicals are usually regarded as stabilizers.
- 55:58They're anti-manic and some are antidepressant also.
- 56:01That's kind of what we're after.
- 56:03And I think in that particular niche, quetiapine stands out more than others.
- 56:08And then antidepressant discontinuation as a stabilizer.
- 56:12So to continue, talked about antidepressants, but antidepressant discontinuation, which
- 56:19leads us to strategies about how to stop antidepressants, because stopping them suddenly or with a relatively rapid taper, as these references indicate, can be a destabilizing
- 56:30event.
- 56:30If you stop an antidepressant too fast, do I start something else or do I just taper?
- 56:35If you stop too fast, you are gonna have problems.
- 56:38So antidepressant discontinuation, too fast, destabilizing.
- 56:43Sometimes you have to go excruciatingly slowly and that's why I add another agent.
- 56:48Yeah, sometimes you'll have to do that because you're going to be tapering for so long.
- 56:52We'll talk about more about that in a minute.
- 56:54Anyway, these are the data supporting the idea that discontinuation itself is a destabilizing event.
- 57:01Likewise, some atypicals can have a destabilizing influence.
- 57:06Really?
- 57:07Which ones?
- 57:08Well,
- 57:08nearly all of them.
- 57:09This reference from 2012 weights the ones that are oldest at that time because they have more case reports.
- 57:18The fact that there are fewer on the more recent ones doesn't mean that incidence is lower.
- 57:22It just means that there wasn't as much time to generate case reports and there was less interest in doing so because, yeah, sure, people know, yeah, some antipsychotics can
- 57:32induce manic symptoms.
- 57:33Aripiprazole, I think in particular.
- 57:35Ziprasidone, I don't know anybody who uses it.
- 57:38Certainly not regularly, I never did.
- 57:40Way too complicated and side effect laden.
- 57:43Olanzapine, love the stuff.
- 57:45Weight gain, oh my God, total disaster.
- 57:48Even olanzapine has case reports of olanzapine-induced mania and certainly risperidone I think is on the more common side, more common than olanzapine.
- 57:57Notice the absence here of quetiapine.
- 57:59I saw that once, almost sure, but I think quetiapine far less likely.
- 58:04How about lurasidone, the new one?
- 58:07New one in the sense that it's the most recently available as a generic.
- 58:10Well, no, see, there's lurasidone too, and in a relatively short period of time, quite a few case reports.
- 58:16So lurasidone, not scot-free for sure.
- 58:19In fact,
- 58:20I started getting too old and fading my way out of direct patient care to accumulate a whole lot of experience with lurasidone.
- 58:26Many of you probably already have more, but in a relatively short period of time, I saw antidepressant-like activation.
- 58:32And so I came to really be mistrustful of lurasidone in this context in the capacity to make things worse while trying to make things better and more stable.
- 58:42All right, so by contrast, the stabilizers.
- 58:45So there's social rhythm therapy, we talked about.
- 58:48Lithium, lamotrigine, and omega-3s.
- 58:50I just want to talk about one in particular because I think it's so important.
- 58:54This is to remind me that if you're starting to fatigue, it's okay, we're nearing, getting close to near the end, but I've saved my single most important hip pocket trick for you
- 59:06for last.
- 59:07You know, I've had a lot of patients referred to me, you've been on this and that and this and that like, I've been on everything.
- 59:13It's hopeless.
- 59:14What am I going to do now?
- 59:16Then I would hope that this trick had not been tried.
- 59:20And it rarely had been.
- 59:21And that was antidepressant discontinuation.
- 59:24Because antidepressants are destabilizers.
- 59:27My hip pocket trick was,
- 59:29"When you got Lamotrigine, were you on an antidepressant?
- 59:32When you got quetiapine, were you on an antidepressant?" And so on.
- 59:36Oh, well, then that means we really don't know what that agent could do for you.
- 59:42We have to go back and maybe do that again.
- 59:45And the first thing that we need to do is help you get off of this antidepressant.
- 59:49So antidepressant discontinuation became one of my mainstay strategies.
- 59:54And you could go, okay, well, let's see, what if that doesn't work?
- 59:58Well, they're on one less medication, which is good because they're usually on several already and maybe you want to add another one.
- 1:00:04The downside of doing this, if you don't make things worse in the process, is minimal.
- 1:00:09Now, there is the risk that their underlying condition could worsen because the antidepressant was really helping them.
- 1:00:15I didn't really see that very much, not on the people who got referred to me.
- 1:00:19And I'm guessing in the people that get referred to you.
- 1:00:21So as you can gather, I'm very fond of this strategy, but the strategy involves technique.
- 1:00:26So, Kaya and all your people, who were wondering differential diagnosis?
- 1:00:34Are they on an antidepressant?
- 1:00:35Maybe you got something that you can do in addition to just like adding something.
- 1:00:40All right, if the antidepressant is working and they're doing great, fine, leave it alone.
- 1:00:43I was so fond of this strategy that one of the senior residents in our program said, "Hey, I think I've done that.
- 1:00:48I think I've seen that too." We put them all together and we wrote up our 12 patients who'd had this response of decreased anxiety, like mixed state symptoms, when they
- 1:00:58discontinued their antidepressant.
- 1:01:00And a bunch of them, their suicidal ideation stopped also.
- 1:01:04All right, so if there's a single key to this, it's take a small first step.
- 1:01:09So, this is not a routine recommendation.
- 1:01:13Mark Horowitz, emphasizes this one down here, the small last steps and the exponential taper, right?
- 1:01:21You can go faster at the beginning, but then you can go slower.
- 1:01:24So exponential tapers, he's got receptor occupancy data to support that as a strategy.
- 1:01:31But even when I talked to Mark Horowitz, he said, "Oh, yeah, I do this small first step too,
- 1:01:37myself," when he's treating patients.
- 1:01:39So a small first step.
- 1:01:42Why am I emphasizing this so much?
- 1:01:44Well, I hope maybe you've got some experience doing this.
- 1:01:47If that first step goes badly, whoa, now we're in big trouble.
- 1:01:51Here we're trying to convince this patient that maybe the way to address her symptoms is just to start tapering that antidepressant.
- 1:01:59If the first step goes badly, she's going to come and- "See, I told you that was a bad idea."
- 1:02:04Now she's kind of stuck on it.
- 1:02:06It would be much harder to ever taper it because you took too big a first step.
- 1:02:11What's a small first step?
- 1:02:13Well, in my hands, it's the smallest step that the patient can confidently engineer.
- 1:02:18Prescribe the lowest possible dose of whatever antidepressant it is.
- 1:02:22Have them cut it in half.
- 1:02:24Have them quarter, if they can manage it.
- 1:02:27If they can really handle it, have them
- 1:02:29look at the small quarters and the big quarters and put them in separate jars and start by taking out the smaller quarter, keeping the, use a big quarter along with the rest of your
- 1:02:39pieces.
- 1:02:40So that we make that step the very smallest we can make.
- 1:02:43Now, when you've made it sound so minute like that, that was on purpose because now your patients would be going, "Oh, well, I mean, that's what, 95 milligrams instead of a
- 1:02:54hundred milligrams?
- 1:02:55I can do that.
- 1:02:55That isn't going to do anything." That's the attitude
- 1:02:58I want.
- 1:02:59Yeah, yeah, sure.
- 1:03:00This will be fine.
- 1:03:01This is not going to mess with anything.
- 1:03:03That's the attitude we need to have them have when they walk out the door to go start this process.
- 1:03:09The smallest possible first step.
- 1:03:11Yeah, there's venlafaxine with its little capsules and beads, right?
- 1:03:15That's a different animal.
- 1:03:16Yeah, there's the slow release, extended release like bupropion, different animal.
- 1:03:21We can talk about those strategies if you want.
- 1:03:23But for most of the rest of them, SRIs, it's pill chopping is going to get you to that smallest fragment.
- 1:03:29If they can't handle quartering it, then halving it is as small as you can get, prescribing the smallest available dose to begin this process.
- 1:03:38They're going to need it at the end anyway, and they'll use up their bigger pieces in the process.
- 1:03:43The next piece of this is the longer they've been on it, the slower the rate they go down.
- 1:03:48People are going to determine this with you.
- 1:03:51If they're anxious to get off, then you can let them go faster and discover, oops, that's too fast.
- 1:03:56And at each step, not taking another step until it's stable again.
- 1:04:01Wherever you were before, you're there again, before we take another step, you've done that before.
- 1:04:07That's kind of the basics of tapering.
- 1:04:10So the speed is you and the patient determine how fast are we going to go based on how anxious are they, how anxious are you?
- 1:04:17I mean, when things are horrible and it's clearly a mixed state, I'm anxious to go fast, as fast as we can dare.
- 1:04:24And we have to learn how fast is that as we go.
- 1:04:27A quarter of a pill per week would be an example.
- 1:04:31And then slowing down again at the end using the small fragments strategy again to make the last steps small.
- 1:04:38But I think it's the first step that really is key.
- 1:04:42So I wrote this up on my website.
- 1:04:44It's in the treatment section.
- 1:04:46If you go to the page about tapering antidepressants, there's the whole rationale that I just offered you.
- 1:04:51There's pages there about tapering bupropion, venlafaxine, tapering by 10% per month as is recommended by one of the patient advocacy groups called survivingantidepressants.org.
- 1:05:02There's a version of this on the YouTube channel as well.
- 1:05:04This is what it looks like.
- 1:05:06My prescription, how are you going to do this?
- 1:05:08That first step down, this is sertraline, for example, using a 25 milligram sertraline, a quartered version of the 25 milligram.
- 1:05:16What's the new dose?
- 1:05:18What pills are you taking?
- 1:05:19What pills are used to get there?
- 1:05:21Right, the date that you started this.
- 1:05:23And just keep doing that down through all these steps.
- 1:05:26They're sort of a pain to make, but you can make them and you can make them on the fly and just do step one, step two.
- 1:05:32So you don't need all this.
- 1:05:33But if you want one of these for every antidepressant, I've got them, email me, there it is.
- 1:05:39And I'll send them to you.
- 1:05:40Okay, so that really is the end.
- 1:05:43This is where we went.
- 1:05:44We're going to take some questions from the chat and then we'll go anywhere you wish to go.
- 1:05:50In adolescence, they've never been on an antidepressant and they come in showing a mixed state, which is a very common presentation as you know in adolescence.
- 1:05:58Would I start with an antidepressant?
- 1:06:00Thank you for asking that question.
- 1:06:01That's really crucial.
- 1:06:02They haven't had a bunch of depressions to know how cyclic it is.
- 1:06:06So we don't know that.
- 1:06:07They haven't had an antidepressant ever.
- 1:06:09So we don't know adverse reactions to antidepressants.
- 1:06:11I'm ticking my way through the non-manic markers, right?
- 1:06:15All I've got left now is age of onset.
- 1:06:18Well, they've got that.
- 1:06:19It's an early age of onset.
- 1:06:20That leaves family history, which I think in this context, you know how important that is.
- 1:06:26Comb the family history.
- 1:06:28You're just trying to get a feeling for who's out there, Uncle Vanya who had this and that.
- 1:06:33You're looking for something like whoops, you're not going, has anyone in your family ever had a diagnosis of bipolar disorder?
- 1:06:40That would be like, that's the rough screen.
- 1:06:43You want the fine tooth comb.
- 1:06:45Tell me about Aunt Jenny and what happened to her.
- 1:06:49Like anybody, the starting question, anybody in your family
- 1:06:52who has had any kind of mood problems at all or serious anxiety problems, function problems, throw a wide net and work from there.
- 1:07:00All right, so you've done all that, you're still having difficulty telling the difference between PTSD, ADHD, depression, bipolar.
- 1:07:08Would you still start with an antidepressant?
- 1:07:10Well, that, as I hope I've now set the stage is up to you
- 1:07:15and your client.
- 1:07:15If you know all this, which you do now, and they know all this, which they do now, it's really just, well, we don't know enough to be like, antidepressant, bad idea.
- 1:07:27We don't know enough to go, you're bipolar, you start with Lamotrigine.
- 1:07:32We don't know enough for that.
- 1:07:33And besides, Lamotrigine, is that enough for like a bad mixed state?
- 1:07:37Maybe we should be thinking about like
- 1:07:39Quetiapine for that or lurasidone, not my favorite, but I don't know enough about it.
- 1:07:44Or we go, no, there's just...
- 1:07:47I've alarmed the family and I'm feeling kind of guilty for how much alarm I've raised.
- 1:07:53And we've decided there's just not enough reason to do something else.
- 1:07:56And we've got to do something.
- 1:07:58We're going to start an antidepressant.
- 1:08:00But they now know that I want to watch
- 1:08:02really quite closely, and they're going to watch closely.
- 1:08:05And we know what we're watching for, which is worsening of this mixed state, worse anxiety, worse sleep, worse racing thoughts, worse agitation, worse irritability.
- 1:08:14And that could start like day one, two, or I'll tell you a little anecdote about how long later it could start.
- 1:08:21And so we're just watching close, is this the right direction or not?
- 1:08:24Now my anecdote, how long after an antidepressant has started is it likely that an antidepressant will make things worse in anyone with bipolar?
- 1:08:33Make things worse in terms of can't sleep, racing thoughts, suicidal ideation, agitation, irritability, physical, like too much energy inside my skin.
- 1:08:44This made me worse.
- 1:08:45How long does that take?
- 1:08:47One of my patients said,
- 1:08:4845 minutes after I started my first dose of Paxil (paroxetine), I felt like I was shot out of a cannon.
- 1:08:54So that's the shortest one, 45 minutes.
- 1:08:57And the longest one is so long that I wrote it up as a case report because I thought it was so important because there was test, retest, reliability.
- 1:09:07This really was causation of a 60-year-old woman who...
- 1:09:13I'll give you the short version.
- 1:09:14Sertraline 100 milligrams comes in looking mixed.
- 1:09:17Uh-oh, stop the antidepressant, takes forever.
- 1:09:20But she finally, with a bunch of mood stabilizers, got things squared away.
- 1:09:24A year later, she calls me up and says, "Hey, you know, I was just never as good as I was on sertraline." She'd had seven years, seven years of great response to sertraline 100
- 1:09:36milligrams, and then comes in with this mixed state.
- 1:09:39Well, a year later,
- 1:09:40she says, "I was never as good as I was." So I started again with like 25 milligrams of sertraline.
- 1:09:46And it's great.
- 1:09:47"I'm calling you up, doc, to tell you that I'm, it's like, I feel like I was!
- 1:09:51Great.
- 1:09:52I was doing great then and I'm doing great now.
- 1:09:54I've taken 25 milligrams yesterday and this morning." So I said, "Well, cool.
- 1:09:59I'm glad to hear this, that you're doing so well.
- 1:10:02Come and see me tomorrow."
- 1:10:04So she comes in the next day after having taken one more dose of 25 milligrams, quarter of her previous dose.
- 1:10:11Same way she looked when I first saw her, mixed state, awful suicidal ideation, that close to putting her in the hospital.
- 1:10:18Three doses, 25 milligrams after seven years of doing great.
- 1:10:23So the answer to the question of how long does it take to an antidepressant make things worse, somewhere between 45 minutes and seven years.
- 1:10:30I hope you
- 1:10:31got a little bit of a laugh out of that.
- 1:10:33Of course, most of this happens within the first couple of days, a week, two weeks.
- 1:10:39By the time you get out a month or so, we can start to relax a little bit, but just obviously not relax too much.
- 1:10:46You replace one medication for another.
- 1:10:48That's better fit for the kingdom.
- 1:10:50Okay, yeah, good.
- 1:10:51I get it.
- 1:10:52Thank you.
- 1:10:53How do I go about lowering dosage, switching medications when the client's on a medication and they're not taking it consistently?
- 1:11:00Well, if my goal is to take the medication out and they're not taking it on a regular basis, well, cool.
- 1:11:06They're most of the way there already.
- 1:11:09Let's take a couple of specific examples.
- 1:11:10Let's say it's an antipsychotic and they are using it intermittently.
- 1:11:14Well, maybe they're using it kind of PRN as needed.
- 1:11:17Maybe we'll just kind of keep that possibility of using it in that fashion.
- 1:11:21And we'll just launch right into starting the new stuff.
- 1:11:24And I wouldn't maybe even necessarily lower the dose.
- 1:11:27They might have figured out what dose it is that helps them.
- 1:11:30None of this is new to you.
- 1:11:31You just kind of
- 1:11:32feel your way along, right?
- 1:11:33I wouldn't make a big deal about trying to get them back on in order to taper it and get on with something else.
- 1:11:39Also kind of basic, but I would be listening for, has this been useful enough to them that we keep it in some role?
- 1:11:47And if that isn't a fair answer, maybe when we go into some face-to-face questions, you can ask that one again if I missed you.
- 1:11:54Dr.
- 1:11:55Fogle asks ketamine, esketamine.
- 1:11:57These are antidepressants and sometimes that's what is needed and it's wonderful that we have these tools available and you can tell where I'm going with this now.
- 1:12:06I have grave concerns about where it leads, like are we just creating a new generation of people who are stuck on ketamine and esketamine.
- 1:12:14Maybe that's a better place to be stuck than where they were, but maybe there was some other way to do this and they wouldn't end up stuck on these things.
- 1:12:22On the other hand, I know of at least one person who had tried a zillion things, had a great response to lithium, for example, knew what being well was and then got a horrible
- 1:12:34side effect from lithium, really uncommon one.
- 1:12:36Can't take lithium anymore.
- 1:12:37And is doing great on repeated doses of ketamine.
- 1:12:40So there are some people out there as you've probably seen who yeah, it's a lifesaver.
- 1:12:45Those are my, you know, yeah, cool, but, but, and I haven't used it.
- 1:12:52I don't send people to go get it because I try to do other things first.
- 1:12:57You might be wondering, well, how much am I practicing these days?
- 1:12:59I'm down to basically indirect consultations and tapered myself out of a role where I was just doing consultations for several years, prior to which I was doing collaborative care
- 1:13:10in primary care where I was just doing remote consultations.
- 1:13:13I did that for a couple of years while I was tapering my way out of direct patient care.
- 1:13:17So here's a patient description.
- 1:13:19I'll come back to that if you're okay.
- 1:13:21So we're going to start there.
- 1:13:23And then we're going to go to maybe some face-to-face stuff Patient presentation: A patient in his late 60s, his wife prefers him in a chemical restraint-like state because
- 1:13:32he's aggressive if not.
- 1:13:34I've recommended Haldol, wife doesn't like it, wanted to DC (discontinue).
- 1:13:38He's on a high dose of Seroquel (quetiapine).
- 1:13:41Any thoughts?
- 1:13:42They assume it's alcohol-induced dementia, or frontotemporal, where he presents with a lot of psych behaviors, aggression, angry outbursts, also appears to have tardive.
- 1:13:51Well, he's already on quetiapine, right?
- 1:13:53So if he's got tardive, then going in the direction of further dopamine blockade is a serious problem.
- 1:14:01So really, this is a question about, is there any way to treat
- 1:14:05agitation and irritability, including physical outbursts, in someone with dementia of one kind or another, maybe we're not sure why, other than high doses of quetiapine.
- 1:14:15I hope that's a fair rephrasing.
- 1:14:17I wouldn't think about haloperidol because of the dopamine blockade problem with the TD history, or even close to risk thereof because frontotemporal dementia, which is in a
- 1:14:26differential here, can be made worse
- 1:14:29by dopamine blockers.
- 1:14:31And so we don't want to go that direction for that reason also.
- 1:14:35So what else is there?
- 1:14:36Oh, it's a grab bag.
- 1:14:38Man, if you can refer this to somebody, this is not my territory.
- 1:14:42And so I'm not a good person to answer this.
- 1:14:44But I can tell you, you've probably already tried to get some other specialist, a psychiatrist who's willing to handle this because this is tough, tough territory.
- 1:14:55I'm obviously not answering your question.
- 1:14:56I think the answer is, the short answer is, I don't know.
- 1:15:00I mean, people do things like gabapentin, neurontin, or divalproex (depakote), which actually has randomized trial data showing it doesn't work.
- 1:15:09But there were responders in that randomized trial.
- 1:15:12So when you're desperate, a negative randomized trial doesn't completely
- 1:15:17deter me when there's little else available.
- 1:15:20So I didn't talk about carbamazepine or its cousin, oxcarbazepine.
- 1:15:26And I think those are unsung, unappreciated alternatives.
- 1:15:31They're sort of a little bit more out there in terms of like, is this the territory of a prescribing psychologist?
- 1:15:38But some of you have been around long enough that I bet you've used them quite a bit.
- 1:15:42And thus have discovered that, yeah, these are full on legit mood stabilizers.
- 1:15:48And I particularly like oxcarbazepine, which I used to think was the weak cousin to carbamazepine.
- 1:15:55And it may actually not have quite as much clout, but
- 1:15:59what we really need is a randomized trial of oxcarbazepine.
- 1:16:02Well, there was one and it was negative, no better than a placebo.
- 1:16:05This was years ago and that kind of ended the research and it was just one trial.
- 1:16:10So I've got a video in the YouTube at PsychEducation about oxcarbazepine, which if you use it much, you might want to watch it because you might want to have patients watch it if
- 1:16:22you're talking about offering that as an option.
- 1:16:25You know about, well, yeah, less need for blood testing.
- 1:16:28I say "less need" because it would be nice to have some liver function tests and TSH beforehand.
- 1:16:34TSH because maybe there's a hyperthyroid component.
- 1:16:39Maybe thyroid is the problem, part of the problem.
- 1:16:42So I'd like to know that.
- 1:16:43So I'd like at least one blood test.
- 1:16:45And then like, well, do you need to do follow-up blood testing?
- 1:16:48And the usual street approach is no.
- 1:16:51Just don't do it because you might discover hyponatremia, the sodium has fallen and freak out and think you have to do something about it like stop oxcarbazepine.
- 1:17:00And if you just never looked, the patient was doing fine.
- 1:17:03In my view, you don't need to look unless there's symptoms: dizziness, confusion, anything even in that direction.
- 1:17:10Yeah, you need to look now at sodium because if you leave it low too long, you can cause seizures,
- 1:17:16even on oxcarbazepine.
- 1:17:17Okay, so oxcarbazepine, carbamazepine are useful tools.
- 1:17:21And maybe in that patient, the 60 year old with dementia, if back is to the wall, can't get anybody to help, maybe oxcarbazepine becomes a candidate as well.
- 1:17:31And I'm just kind of shooting from the hip there, not my territory.
- 1:17:34And obviously there's more information about all those things at some of the resources that I mentioned.
- 1:17:39Hi, Makayla.
- 1:17:41I just want to first say thank you for coming on and sharing.
- 1:17:45It's been extremely interesting listening to you.
- 1:17:48And I feel like I've learned quite a bit, especially in the mixed sector of the bipolar disorder kind of spectrum.
- 1:17:55I just wanted to ask, because I come from a small farm town.
- 1:18:00I don't know if you've worked with a lot of farmers, but I know when it comes to my community,
- 1:18:05they are extremely hard to not only get in the office, but just to work with.
- 1:18:11Yeah, Makayla, I live in Corvallis, Oregon.
- 1:18:14I'm surrounded by farm fields.
- 1:18:16And so even though I have a couple of urban communities that patients come from, including Corvallis itself, yeah, I think I know what you're talking about.
- 1:18:24Continue please.
- 1:18:24I just wanted to ask,
- 1:18:26have you ever had to implement any sort of strategy to get them into the office?
- 1:18:30Or...
- 1:18:31I'm assuming there's some sort of rapport building that you do to, you know, basically ensure them that if they do come in, they're going to be treated proper and treated well.
- 1:18:43Yeah, indeed.
- 1:18:44Very thoughtful question.
- 1:18:45Well, obviously, lowering all possible barriers, insurance barriers,
- 1:18:50phone contact barriers, and then ensuring that like our front office staff, wonderful people.
- 1:18:55If anyone makes it as far as the front office, like on a phone, I want them to have a good experience on the phone.
- 1:19:00That's the obvious stuff.
- 1:19:02If you have a look at my YouTube stuff or my website stuff, I've tried to do the same thing there.
- 1:19:06What's it like to show up?
- 1:19:08You need to be encouraged for just having shown up here.
- 1:19:11And then we'll go from there.
- 1:19:12So kind of congratulating you on having shown up.
- 1:19:16How about outreach into the community?
- 1:19:18Well, doing presentations and being a really nice person who talks in a very understandable way.
- 1:19:24It makes it clear that, you know, sure, mental health problems are common.
- 1:19:28We all have them; many people have them.
- 1:19:30Getting treatment is...
- 1:19:32you know, the whole shtick about destigmatizing
- 1:19:35mental health in public places as another barrier-lowering strategy.
- 1:19:42And perhaps you have some to add?
- 1:19:45So for me, I, as I mentioned before, I come from a small farm town.
- 1:19:49I'm actually from Visalia, California.
- 1:19:52So we've got a lot of people in dairy, a lot of people in nuts, a lot of people in citrus, just all walks of life.
- 1:19:59And I know personally that the culture that
- 1:20:04is in my hometown when it comes to mental illness is...
- 1:20:09I'm not gonna sugarcoat it.
- 1:20:10It's a little ugly.
- 1:20:11We definitely have a mentality of "I'd rather die, I'd rather kill myself than become unable to work, then let other people see me as a burden" or so on and so forth.
- 1:20:25So for me personally, working with my community,
- 1:20:28I've really had to handle people's shame about coming in.
- 1:20:32So as you said, just, I mean, talk nice, just you deserve to be here.
- 1:20:37Your problems deserve to be heard and helped and listened to.
- 1:20:42And just because you are reaching out doesn't make you any weaker than your fellow man.
- 1:20:48Yeah, well put.
- 1:20:49Two resources for that
- 1:20:51to add to your toolkit: One is there's a program about self-stigma in bipolar disorder and treating it.
- 1:20:59And so there's a whole treatment program around treating self-stigma.
- 1:21:03And if you search self-stigma, and the person behind this is Andrea Vassilev, V-A-S-S-I-L-E-V.
- 1:21:13An underappreciated
- 1:21:14realm in bipolar disorder is how much stigma people carry without being stigmatized from the exterior, from the interior.
- 1:21:21And Dr.
- 1:21:22Vassilev has developed a whole program for that.
- 1:21:24It's called "Overcoming Self-Stigma." Search that.
- 1:21:27It's already available if you search it.
- 1:21:30That's one more thing you can offer people.
- 1:21:32And then lastly, and then I'll jump to other questions in the chat.
- 1:21:35This video that we have coming out, I hope it's going to destigmatize bipolar disorder a whole bunch further.
- 1:21:41A general in the US Army, a woman who worked in the Obama White House,
- 1:21:45a woman who was non-functional for nearly 40 years who runs her own consulting company now.
- 1:21:51Anyway, some great examples of I was hammered and now I'm doing really well.
- 1:21:56Part of explaining the science of bipolar in that film.
- 1:21:59We're really looking forward to having that come out.
- 1:22:01So thank you, Makayla, for your questions.
- 1:22:04One comment I'd like to make, and it may not be your area in which you practice, but as you talk about mixed states, I needed to think about how this applies to the pediatric
- 1:22:18late teen and young adult patients in particular, because in that age group, it is far more rare to present a pure syndrome.
- 1:22:29Not only mixed to make it more confusing.
- 1:22:32Then there's substance use, which can produce typical mixed state symptoms.
- 1:22:38Are you using anything?
- 1:22:39Oh, no, no.
- 1:22:42Let's see.
- 1:22:42The probability is pretty high that you are or have been and have tinkered with it at least.
- 1:22:47And so, you know, from experience, trying to figure out how to develop enough rapport to get a straight answer to that question without having to go to, well, we're going to give
- 1:22:57you a urine screen, which has always felt to me like, dude, you have to order a urine screen?
- 1:23:04You have so little rapport with your patient that you had to resort to that?
- 1:23:08You have other problems besides just whether or not they're using substances in terms of your treatment alliance.
- 1:23:12And so that would be the last resort strategy in my book.
- 1:23:16In any case, George, actually, you probably have more experience than I do in terms of kids presenting in mixed states.
- 1:23:24And we had our one question already about like, well, hey, Phelps, how far would you go?
- 1:23:29I mean, okay, we're going to prescribe an antidepressant.
- 1:23:31Well,
- 1:23:32because of where I've been, I have to go, you have to push me pretty far to think about prescribing an antidepressant.
- 1:23:38I did it in the free clinic.
- 1:23:39I hardly ever did it in my hospital-based outpatient practice.
- 1:23:43So George, maybe from your experience, pearls of wisdom about identifying and treating mixed states in kids?
- 1:23:51Well, I think some of challenges are, like you said, the caution about
- 1:23:57your goal to be on antidepressants is very well taken.
- 1:24:01I tend to prefer some of the mood stabilizers.
- 1:24:05One challenge with the pediatric population is that there's not nearly as much data as there is with adults in terms of which stabilizers have the highest likelihood of working.
- 1:24:17But I would completely agree with your basic tenet, which is
- 1:24:21when they're seeing symptoms that indicate some possible mixed mood disturbance, starting with mood stabilizers.
- 1:24:31I'm aware, I'm reminded that you and many of your colleagues face this dilemma: "That treatment is not FDA-approved." Oh my God, I hate the sound of that.
- 1:24:41Like, it's what the FDA disapproves of this treatment.
- 1:24:44No, no, we understand that it just means that this technical hurdle has not been cleared.
- 1:24:49But lamotrigine, lithium, not FDA-approved for the treatment of anything, hardly, except for narrow niches.
- 1:24:56Well, that means like nothing in the adult world, but in the kids, it's not FDA-approved.
- 1:25:01So you have to go through the whole song and dance of explaining and documenting that you've done the whole PAR (procedures, alternatives, risks), around why you're considering
- 1:25:12these things that are not FDA-approved.
- 1:25:16This makes the job that much harder.
- 1:25:18And I appreciate that additional level of difficulty.
- 1:25:21And I'm just going to offer a couple closing thoughts.
- 1:25:24First is, I have a lot of respect for what you're doing.
- 1:25:28And those of you who are contemplating getting prescribing privileges, I have a lot of respect for what you're setting out to do after having already earned your PhD or PsyD.
- 1:25:38And we so need you and I appreciate the fact that you are taking that on or have taken it on.
- 1:25:45I'm excited to become a spokesperson for us psychiatrists, at least there's one, who thinks like that about you.
- 1:25:52George has put me in touch with some people.
- 1:25:54So I just want you to know that, yep, there's one psychiatrist anyway, who's endorsing what you're doing and that there ought to be more of you.
- 1:26:02And thank you for coming this evening.
- 1:26:06And thank you for supporting us.
- 1:26:08I would like to remind people that Alliant University has a fantastic clinical psychopharmacology program.
- 1:26:09Thank you for a wonderful presentation.
- 1:26:14So if you want to delve more deeply, seriously into not just being able to prescribe, but also understanding on a much, much deeper level, what may be happening with your clients
- 1:26:25in terms of pharmacology, please know it is a program.
- 1:26:30So please contact us, contact Dr.
- 1:26:32Kapalka.
- 1:26:33I'm philip.dietz@alliant.edu.
- 1:26:36And I'll let you have the last words, Dr.
- 1:26:38Kapalka.
- 1:26:39Is there anything you want to add before we shut down?
- 1:26:41Thank you once again.
- 1:26:43Thank you, Dr.
- 1:26:44Phelps
- 1:26:44for your support of our profession, but also for all you do for your patients and for practicing in an area that is so complex and so nuanced.
- 1:26:56And we really need more providers: psychiatrists, prescribing psychologists, psychiatric nurses.
- 1:27:02And hope everyone enjoyed and we hope to see you next time.